{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:54:54Z","timestamp":1794545694339,"version":"4.9.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.annonc.2024.08.2241","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T08:46:51Z","timestamp":1726303611000},"page":"981-992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":204,"title":["Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial"],"prefix":"10.1016","volume":"35","author":[{"given":"B.J.","family":"Monk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Barretina-Ginesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Graybill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.C.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vulsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Haslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J. Rubio","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"DiSilvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bruchim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Shtessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.A.","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2024.08.2241_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2241_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.annonc.2024.08.2241_bib3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.annonc.2024.08.2241_bib4","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.22.01934","article-title":"PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian Cancer: ASCO Guideline Rapid Recommendation Update","volume":"40","author":"Tew","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2024.08.2241_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2024.08.2241_bib9","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2024.08.2241_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2024.08.2241_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2024.08.2241_bib13","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"issue":"4","key":"10.1016\/j.annonc.2024.08.2241_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.annonc.2024.08.2241_bib15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2024.01.021","article-title":"Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"184","author":"Pothuri","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2024.08.2241_bib16","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ijgc-2019-000441","article-title":"Joint ENGOT and GOG Foundation requirements for trials with industry partners","volume":"29","author":"Vergote","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2241_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2022.04.012","article-title":"Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA\/ENGOT-OV26\/GOG-3012 study","volume":"166","author":"O'Cearbhaill","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2024.08.2241_bib18","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/cncr.34706","article-title":"Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"129","author":"Mirza","year":"2023","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2024.08.2241_bib19","first-page":"CD007565","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"2011","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annonc.2024.08.2241_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2024.07.006","article-title":"Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: an ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012","volume":"189","author":"Kamrava","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2241_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ygyno.2022.06.028","article-title":"Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - pooled analysis from the PRIMA trial","volume":"166","author":"Chase","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.08.2241_bib22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","article-title":"Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials","volume":"121","author":"Matulonis","year":"2015","journal-title":"Cancer"},{"issue":"34","key":"10.1016\/j.annonc.2024.08.2241_bib23","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A\u00a0randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2024.08.2241_bib24","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2024.08.2241_bib25","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.08.2241_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095285","article-title":"The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2241_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2024.08.2241_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.08.2241_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40487-023-00227-6","article-title":"Real-world outcomes following first-line treatment in patients with advanced ovarian cancer with multiple risk factors for disease progression who received maintenance therapy or active surveillance","volume":"11","author":"Chase","year":"2023","journal-title":"Oncol Ther"},{"key":"10.1016\/j.annonc.2024.08.2241_bib30","article-title":"Association of multiple high-risk factors on observed outcomes in real-world patients with advanced ovarian cancer treated with first-line therapy","volume":"7","author":"Chase","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"10.1016\/j.annonc.2024.08.2241_bib31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"30","key":"10.1016\/j.annonc.2024.08.2241_bib32","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2241_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114157","article-title":"Tolerability of the niraparib individualized starting dose in the PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib first-line maintenance therapy","volume":"208","author":"Vulsteke","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2024.08.2241_bib34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2241_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/curroncol29010029","article-title":"Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Pagkali","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2241_bib36","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.08.2241_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2024.08.2241_bib38","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.08.2241_bib39","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424037621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424037621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T12:14:28Z","timestamp":1732277668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424037621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0923753424037621"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2241","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}